Japan Moves to Safeguard Pharmaceutical Supply Chain from China
Japan is taking proactive steps to protect its pharmaceutical supply chain for the future amidst concerns that China could potentially use exports as leverage in bilateral relations. Analysts point to past instances, such as China limiting rare earth mineral shipments to Japan in 2010, as a precedent for such actions.
Japanese authorities are urging local pharmaceutical companies to ramp up investments in manufacturing essential medicine ingredients to reduce reliance on Chinese imports. Kazuhiro Tateda, president of the Japan Association of Infectious Diseases, noted that the government is gearing up for potential crises, although belatedly.
Last year, Japan imported $451 million worth of pharmaceutical products from China, comprising less than 1% of total imports in the sector. In comparison, the US remains the largest supplier of pharmaceutical products to Japan, accounting for over 21% of total imports.
[ad_2]
Source link
